Stratophase, the UK-based biopharmaceutical services and technology company, has confirmed its membership of the recently established National Institute for Innovation in Manufacturing Biopharmaceuticals in the US.
The company’s membership was signed at NIIMBL’s inaugural meeting in Washington DC in May 2017, which was attended by Stratophase’s CEO Simon Saxby.
The important role of specialist small and medium sized enterprises (SMEs) in the future success of NIIMBL is considered to be vital, and Stratophase is pleased to confirm it is among the first SMEs to join the organisation.
NIIMBL is the eleventh institute in the Manufacturing USA network and the first to be funded by the US Department of Commerce. It was launched by US Secretary of Commerce Penny Pritker in December 2016 with an award of $70 million.
In addition to advancing the US’s leadership in the biopharmaceutical industry, the institute also aims to foster US economic development, innovate the manufacturing of medical treatments and ensure a future qualified workforce by collaborating with educational institutions.
It aims to raise $250 million that will then be disbursed as awards to fund projects proposed by teams drawn from the membership.
It is anticipated that each team may include a blue chip biopharma organisation, SMEs and academic groups.
Commenting on Stratophase’s membership of NIIMBL, CEO Simon Saxby said: “As an innovative biotech services and technology company, we are acutely aware of how important the US market is to Stratophase."
"Joining NIIMBL as a founder member demonstrates how serious we are about continuing to forge links with the US biopharmaceutical manufacturing sector."
"We are looking forward to our active involvement in the industrial and academic collaborations that will be enabled by being part of NIIMBL during the coming months and years.”
